Skip to Content
Merck
  • Characterization of a second vaccinia virus mRNA-decapping enzyme conserved in poxviruses.

Characterization of a second vaccinia virus mRNA-decapping enzyme conserved in poxviruses.

Journal of virology (2007-09-21)
Susan Parrish, Bernard Moss
ABSTRACT

Vaccinia virus (VACV) encodes enzymes that cap the 5' end of viral mRNAs, which enhances their stability and translation. Nevertheless, recent studies demonstrated that the VACV D10 protein (VACV-WR_115) decaps mRNA, an enzymatic activity not previously shown to be encoded by a virus. The decapping activity of D10 is dependent on a Nudix hydrolase motif that is also present in the VACV D9 protein (VACV-WR_114), which shares 25% sequence identity with D10. Here, we showed that a purified recombinant VACV D9 fusion protein also decaps mRNA and that this activity was abolished by point mutations in the Nudix hydrolase motif. Decapping was specific for a methylated cap attached to RNA and resulted in the liberation of m7GDP. D9 differed from D10 in requiring a longer capped RNA substrate for optimal activity, having greater sensitivity to inhibition by uncapped RNA, and having lower sensitivity to inhibition by nucleotide cap analogs unattached to RNA. Since D9 is expressed early in infection and D10 late, we suggest that the two proteins enhance mRNA turnover and manipulate gene expression in a complementary and overlapping manner.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
7-Methylguanosine 5′-diphosphate sodium salt, ≥92.5%